Corporate News 25-Jun-24
USFDA classifies inspection of Cipla's Patalganga unit as 'Voluntary Action Indicated'
Cipla announced that the United States Food and Drug Administration (USFDA) vide communication dated 25 June 2024 has classified the inspection of the company's manufacturing facility in Patalganga as Voluntary Action Indicated (VAI).
Previous News
Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India
( Corporate News - 28-Jun-24 19:23 )
Cipla Ltd eases for fifth straight session
( Hot Pursuit - 25-Jun-24 13:35 )
USFDA classifies inspection of Cipla's Patalganga unit as 'Voluntary Action Indicated'
( Corporate News - 25-Jun-24 12:12 )
Cipla gets VAI classification from USFDA for Patalganga facility
( Hot Pursuit - 25-Jun-24 11:34 )
Cipla slides as Goa facility gets 6 USFDA observations
( Hot Pursuit - 24-Jun-24 09:47 )
Cipla Goa facility gets 6 USFDA observations
( Hot Pursuit - 22-Jun-24 16:22 )
Cipla's Goa unit completes USFDA inspection
( Corporate News - 22-Jun-24 11:47 )
Cipla to invest additional EUR 3 million in Ethris GmbH
( Corporate News - 18-Jun-24 17:19 )
Cipla hits record high as UK arm plans to invest additional 3 mln euro in Ethris
( Hot Pursuit - 18-Jun-24 14:56 )
Cipla allots 72,263 equity shares under ESOS
( Corporate News - 10-Jun-24 18:18 )
Cipla Ltd up for third straight session
( Hot Pursuit - 05-Jun-24 13:05 )
Other Stories
Lesha Industries to convene board meeting
29-Jun-24 17:39
Elecon Engineering Company to conduct board meeting
29-Jun-24 17:39
Mahamaya Steel Industries schedules AGM
29-Jun-24 17:38
Vivimed Labs to hold board meeting
29-Jun-24 17:38
3C IT Solutions and Telecoms (India) to hold board meeting
29-Jun-24 17:38
Purple Finance to consider fund raising
29-Jun-24 17:38
UGRO Capital to discuss results
29-Jun-24 17:38
Vivanza Biosciences to hold board meeting
29-Jun-24 17:37
Samrat Pharmachem to declare Quarterly Result
29-Jun-24 17:37
VL E-Governance & IT Solutions announces board meeting date
29-Jun-24 17:37
Back
Top
